Sinovac Receives RMB 87 Million Purchase Order for Healive from China's Ministry of Public Health On Tuesday

Receives RMB 87 Million Purchase Order for Healive from China's Ministry of

Tuesday April 28, 2009, 8:00 am EDT

April 28 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading

developer and provider of vaccines in China, today announced that the Company

has received a purchase order for approximately RMB 87 million, or $12.8

million, of its inactivated hepatitis A vaccine, Healive , from China's Ministry

of Public Health (MOH). The MOH's order is supported by Sinovac's newly

completed filling and packaging plant that has increased Sinovac's annual

capacity to 20 million doses. Sinovac is currently the sole provider of the

hepatitis A vaccine to the MOH for this tender.

the government's larger scale efforts to improve public health, the hepatitis A

vaccination campaign will cover young children from 18 months to 12 years old in

32 cities or counties in nine provinces and is intended to expand the

vaccination coverage of hepatitis A throughout China. Healive is widely

recognized as a safe and high-quality vaccine against the hepatitis A virus. In

2008, Sinovac collaborated with the MOH to supply its hepatitis A vaccine to

people living in the disaster area following the major earthquake that occurred

in Sichuan province.

Weidong Yin, Chairman, President and CEO, commented, "We are very pleased to

have established a public market for our inactivated hepatitis A vaccine,

Healive, through this supply agreement with the MOH, as we are focusing our

efforts in 2009 on both the public and private pay markets. We believe this is a

good beginning when we start developing public market for Healive. Sinovac

continues to develop and commercialize a variety of vaccines in order to fulfill

our mission to eliminate infectious disease. With an annual capacity of 20

million doses at our newly completed filling and packaging plant, we are well

positioned to fulfill existing orders, increase our production scale for meeting

the demand from both public market and private market and develop new vaccines.

Although we are experiencing the global financial crisis, the medical reform

provides positive supports to the health care industry in China. We will keep

executing our corporate strategy, and leverage the opportunities that we are

facing to grow our business."

Biotech Ltd. is a China-based biopharmaceutical company that focuses on the

research, development, manufacture and commercialization of vaccines that

protect against human infectious diseases. Sinovac's commercialized vaccines

include Healive (hepatitis A), Bilive (combined hepatitis A and B), Anflu

(influenza) and Panflu(TM) (H5N1). Sinovac is currently developing a universal

pandemic influenza vaccine and Japanese encephalitis vaccine. Its wholly-owned

subsidiary, Tangshan Yian is currently conducting field trials for the first

domestically-developed inactivated animal rabies vaccines. Additional

information about Sinovac is available on its website, http://www.sinovac.com

. To be added to our distribution list, please email: info@sinovac.com.

contains forward-looking statements. These statements are made under the

"safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of

1995. These forward-looking statements can be identified by words or phrases

such as "will," "expects," "anticipates," "future," "intends," "plans,"

"believes," "estimates" and similar statements. Among other things, the business

outlook and quotations from management in this press release contain

forward-looking statements. Statements that are not historical facts, including

statements about Sinovac's beliefs and expectations, are forward-looking

statements. Forward-looking statements involve inherent risks and uncertainties.

A number of important factors could cause actual results to differ materially

from those contained in any forward- looking statement. Sinovac does not

undertake any obligation to update any forward-looking statement, except as

required under applicable law.

more information, please contact:

Tel: +86-10-8289-0088

Fax: +86-10-6296-6910

Carrington/Amy Glynn

Tel: +1-646-536-7017/7023

Tel: +1-656-536-7033